The CHD Exome+ Consortium is a collaboration of 9 studies to identify genetic determinants of coronary heart disease and cardiovascular risk factors. All studies have had a customised version of the Illumina Exome array assayed, with a total of 40,000 coronary disease cases and 45,000 disease-free controls. In addition to two South Asian studies led by the CEU (BRAVE and PROMIS), the consortium includes seven studies of European ancestry participants: Copenhagen City Heart Study, Copenhagen General Population Study, Copenhagen Ischemic Heart Disease Study, EPIC-CVD, MORGAM, PROSPER and WOSCOPS.

Exemplar publications:

Gregson JM, Freitag DF, Surendran P et al., 2016. Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2 lowering alleles. Eur J Prev Cardiol (in press).

Surendran P, Drenos F, Young R et al., 2016. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nat Genet 48(10):1151-61.

Stitziel NO, Stirrups KE, Masca NG et al., 2016. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med 374(12):1134-44.

 

Zanoni P, Khetarpal SA, Larach DB et al., 2016. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science 351(6278):1166-71.